ArticleJournal of health, population, and nutrition2026
Association of medical visit frequency with cardiovascular events and mortality in patients with dyslipidaemia: a cohort study using a Japanese claims database.
Article in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDyslipidaemia is a major risk factor for cardiovascular and cerebrovascular diseases; however, the optimal frequency of medical visits remains unclear.
objectiveTo examine whether medical visit frequency is associated with the incidence of cardiac events, cerebrovascular events, and mortality among patients initiating lipid-lowering therapy.
methodsWe conducted a retrospective cohort study using data from the Shizuoka Kokuho Database between April 1, 2012, and September 30, 2021. Patients initiating lipid-lowering therapy were classified into high-frequency (≥ 22 visits in 2 years) and low-frequency (8-12 visits in 2 years) groups. After 1:3 propensity score matching and exclusion of patients with events within 2 years, 1,435 patients in the low-frequency group and 4,412 in the high-frequency group were analysed.
resultsOver a mean follow-up of 5.3 years, composite outcomes occurred in 5.6% of both groups (hazard ratio [HR] 1.08; 95% confidence interval [CI] 0.84-1.38; p = 0.571). No significant differences were observed for cardiac events (HR 1.13; 95% CI 0.83-1.54), cerebrovascular events (HR 1.13; 95% CI 0.67-1.90), or mortality (HR 0.94; 95% CI 0.60-1.48).
conclusionLess frequent visits were not associated with increased risks of cardiovascular events or mortality. Extending visit intervals may therefore be a reasonable option for selected stable patients receiving lipid-lowering therapy for primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.